Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.5.4.4 (adenosine deaminase)
 5,136 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixty-three patients with acute progressive tuberculosis (APPT) underwent splenic ultrasound radiation (SUSR) (Group 1) for evaluation of the efficiency of the procedure. A hundred and twenty five patients with APPT were treated without SUSR (Group 2, controls). An experimental study was also conducted on 290 mice. SUSR was also used in the late first month of antituberculous chemotherapy. A procedure for SUSR is described in the paper. There were most favourable clinical and X-ray changes in Group 1 than in Group 2 just after SUSR and at the end of the treatment course. After the procedure (first control) all biochemical inflammation indices (medium molecular-weight molecules, adenosine deaminase, fibrinogen, sialic acids) were significantly decreased in Group 1. Immunological indices were insignificantly changed between groups and primary investigations. A study after two months of SUSR showed no differences in biochemical indices in the groups and in this period as compared to the control one. At the same time, the levels of CD cells, especially CD8+, were found to be lower in Group 2. In Group 1, the count of CD cells and their functional activity by the blast transforming reaction on PHA were stable and significantly higher than in Group 2. The experimental study demonstrated that the levels of medium molecular-weight molecules and the index of lung damage reduced after SUSR. The decrease in the count of MBT colonies and a positive response in the murine paw test, which is indicative of T-cell immunodeficiency, were detected one month following the procedure (distant control). So SUSR should be proposed as a new effective pathogenetic treatment for APPT.
 ...
PMID:[Effectiveness of the use of ultrasound irradiation of the spleen in patients with acutely progressive pulmonary tuberculosis]. 1222 45

Better understanding of the pathogenesis and treatment of primary systemic vasculitides (PSV) has led to the development of many potentially clinically relevant biomarkers. Genome-wide association studies have highlighted that MHC class II polymorphisms may influence the development of particular anti-neutrophil cytoplasmic antibody (ANCA) serotypes, but not the clinical phenotype of ANCA-associated vasculitis (AAV). Although ANCAs are overall poor biomarkers of disease activity, they may be useful for the prediction of flares of renal and/or pulmonary vasculitis. Moreover, patients with proteinase 3 (PR3)-AAV may respond better to rituximab than cyclophosphamide. Newer biomarkers of renal vasculitis in AAV include urinary soluble CD163, and may in the future reduce the requirement for renal biopsy. Better understanding of dysregulated neutrophil activation in AAV has led to the identification of novel biomarkers including circulating microparticles, and neutrophil extracellular traps (NETs), although their clinical utility has not yet been realised. Studies examining endothelial injury and repair responses have additionally revealed indices that may have utility as disease activity and/or prognostic biomarkers. Last, next-generation sequencing technologies are revealing monogenic forms of vasculitis, such as deficiency of adenosine deaminase type 2 (DADA2), and are profoundly influencing the approach to the diagnosis and treatment of vasculitis in the young.
 ...
PMID:Vasculitis update: pathogenesis and biomarkers. 2878 84